$11.91
3.09%
NYSE, Thu, Oct 01 2026.
ISIN
CA23256X4075
Symbol
CYBN

Cybin Stock price

$11.91
+0.31 2.67% 1M
+6.92 138.68% 6M
+3.73 45.60% YTD
+5.93 99.16% 1Y
-9.75 45.01% 3Y
-71.31 85.69% 5Y
-37.73 76.01% 10Y
-37.73 76.01% 20Y
NYSE, Closing price Thu, Oct 01 2026
-0.38 3.09%
ISIN
CA23256X4075
Symbol
CYBN
Industry

Is Cybin a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.4m
Enterprise Value
$-115.6m
Net debt
positive
Cash
$117.0m
Shares outstanding
62.0m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
1.2 | 1.0
P/B
0.0
Financial Health
Equity Ratio
92.3%
Return on Equity
-
ROCE
-70.3%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$15.3m | -
SBC as % of FCF
-
SBC Growth 1Y
-25.6%
Share Count Growth 1Y
169.1%
Shareholder Yield
-169.1%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-119.6m
EBIT
$-119.7m
Net Income
$-120.4m
Free Cash Flow | ex SBC
$-100.0m | $-115.3m
Growth
Revenue | estimate
- | -
EBITDA
-15.6%
EBIT
-15.4%
Net Income
-39.3%
Free Cash Flow
-34.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.3
FCF per Share
$-1.6
Short interest
0.5%
Employees
-
Rev per Employee
-

Cybin Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cybin forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Cybin forecast:

Buy
86%
Hold
14%

Financial data from Cybin

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
24% 24%
-
- Research and Development Expense 72 72
65% 65%
-
-120 -120
16% 16%
-
- Depreciation and Amortization 0.08 0.08
69% 69%
-
EBIT (Operating Income) EBIT -120 -120
15% 15%
-
Net Profit -120 -120
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cybin directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Head office Canada
CEO Mr. So
Website www.helus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today